Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of ustekinumab as intravenous (IV: into the vein) infusion in induction study in participants with moderately to severely active Ulcerative Colitis (UC) and as subcutaneous (SC) administration in maintenance study in participants with moderately to severely active Ulcerative Colitis (UC) who have demonstrated a clinical response to Induction treatment with IV ustekinumab.


Options:
A: Arm Label: Golimumab induction responders (GLM-I-Rsp)-Placebo Maintenance; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Biological: Golimumab 100 mg | Arm Label: GLM-I-Rsp-Golimumab 50 mg Maintenance; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 50 mg, Biological: Golimumab 100 mg | Arm Label: GLM-I-Rsp-Golimumab 100 mg Maintenance; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 100 mg, Biological: Golimumab 200 mg | Arm Label: Placebo induction responders (PBO-I-Rsp)-Placebo Maintenance; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Biological: Golimumab 100 mg | Arm Label: PBO-I-nonRsp-Golimumab 100 mg Maintenance; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 100 mg | Arm Label: GLM-I-nonRsp-Golimumab 100 mg Maintenance; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 100 mg | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Golimumab induction responders (GLM-I-Rsp)-Placebo Maintenance, Placebo induction responders (PBO-I-Rsp)-Placebo Maintenance | Intervention Type: BIOLOGICAL; Name: Golimumab 50 mg; Assigned to Arm(s): GLM-I-Rsp-Golimumab 50 mg Maintenance | Intervention Type: BIOLOGICAL; Name: Golimumab 100 mg; Assigned to Arm(s): GLM-I-Rsp-Golimumab 100 mg Maintenance, GLM-I-Rsp-Golimumab 50 mg Maintenance, GLM-I-nonRsp-Golimumab 100 mg Maintenance, Golimumab induction responders (GLM-I-Rsp)-Placebo Maintenance, PBO-I-nonRsp-Golimumab 100 mg Maintenance, Placebo induction responders (PBO-I-Rsp)-Placebo Maintenance | Intervention Type: BIOLOGICAL; Name: Golimumab 200 mg; Assigned to Arm(s): GLM-I-Rsp-Golimumab 100 mg Maintenance
B: Arm Label: Induction Study - Placebo Intravenous (IV); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo IV | Arm Label: Induction Study - Ustekinumab 130 milligram (mg) IV; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab IV | Arm Label: Induction Study - Ustekinumab 6 mg/kg IV; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab IV | Arm Label: Induction Study- Placebo- Nonresponsders at Week 8; Type: OTHER; Interventions: Drug: Placebo SC, Drug: Ustekinumab IV | Arm Label: Induction study-Ustekinumab Nonresponders at Week 8; Type: OTHER; Interventions: Drug: Placebo IV, Drug: Ustekinumab SC | Arm Label: Maintenance Study - Placebo Subcutaneous (SC); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo SC | Arm Label: Maintenance Study - Ustekinumab 90mg SC every 12 weeks; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab SC | Arm Label: Maintenance Study - Ustekinumab 90mg SC every 8 weeks (q8w); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab SC | Arm Label: Maintenance Study - Placebo IV - Responder - Placebo SC; Type: OTHER; Interventions: Drug: Placebo SC | Arm Label: Maintenance Study-Delayed Responder-Ustekinumab 90mg SC q8w; Type: OTHER; Interventions: Drug: Ustekinumab SC | Intervention Type: DRUG; Name: Placebo IV; Assigned to Arm(s): Induction Study - Placebo Intravenous (IV), Induction study-Ustekinumab Nonresponders at Week 8 | Intervention Type: DRUG; Name: Placebo SC; Assigned to Arm(s): Induction Study- Placebo- Nonresponsders at Week 8, Maintenance Study - Placebo IV - Responder - Placebo SC, Maintenance Study - Placebo Subcutaneous (SC) | Intervention Type: DRUG; Name: Ustekinumab IV; Assigned to Arm(s): Induction Study - Ustekinumab 130 milligram (mg) IV, Induction Study - Ustekinumab 6 mg/kg IV, Induction Study- Placebo- Nonresponsders at Week 8 | Intervention Type: DRUG; Name: Ustekinumab SC; Assigned to Arm(s): Induction study-Ustekinumab Nonresponders at Week 8, Maintenance Study - Ustekinumab 90mg SC every 12 weeks, Maintenance Study - Ustekinumab 90mg SC every 8 weeks (q8w), Maintenance Study-Delayed Responder-Ustekinumab 90mg SC q8w
C: Arm Label: Rectal tacrolimus; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rectal tacrolimus | Arm Label: Rectal Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rectal tacrolimus; Assigned to Arm(s): Rectal tacrolimus | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Rectal Placebo
D: Arm Label: Vedolizumab; Type: EXPERIMENTAL; Interventions: Drug: vedolizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: vedolizumab; Assigned to Arm(s): Vedolizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B